French-Belgian medtech startup neuroClues is revolutionizing the way brain health issues are diagnosed with their high-speed eye-tracking technology. By incorporating AI-driven analysis, the company aims to make it easier for healthcare providers to detect neurodegenerative conditions using eye movements.
Currently focusing on Parkinson’s disease, neuroClues’ portable headsets can capture eye movements at an impressive 800 frames per second. This data can then be analyzed in just a few seconds, providing clinicians with valuable insights for diagnosis.
The founders of neuroClues, both neuroscience researchers, are driven by the high rates of misdiagnosis in Parkinson’s disease. Their ultimate goal is to create a device that acts as a “stethoscope for the brain,” offering quick brain health scans during routine optician visits.
In addition to Parkinson’s, neuroClues envisions their technology being used to test for other conditions such as concussion, Alzheimer’s, MS, and stroke. The startup is currently in the process of seeking FDA approval for clinical use in the US and anticipates regulatory approval in the EU by 2025.
With a focus on developing their own hardware and software, neuroClues boasts unrivaled speed of data capture at 800 frames per second. Their innovative approach has garnered the attention of investors, leading to a recent €5 million pre-Series A funding round.
Looking ahead, neuroClues plans to expand their market reach and aims to have their diagnostic device in the hands of every neurologist in the US and Europe by 2026-2027. With a strong foundation of funding and support, neuroClues is poised to revolutionize the field of brain health diagnostics.